Abstract and Introduction
Context: Menopause, the permanent cessation of menses, reflects oocyte depletion and loss of gonadal steroids. It is preceded by a transition state, the perimenopause, which is characterized by the gradual loss of oocytes, altered responsiveness to gonadal steroid feedback, wide hormonal fluctuations, and irregular menstrual patterns. The goal of this mini-review is to discuss the basic pathophysiology of the menopausal transition and the hormonal and nonhormonal management of clinicopathology attributed to it.
Evidence Acquisition: A Medline search of epidemiologic, population-based studies, and studies of reproductive physiology was conducted. A total of 758 publications were screened.
Evidence Synthesis: The reproductive hormonal milieu of the menopausal transition precipitates bothersome vasomotor symptoms, mood disruption, temporary cognitive dysfunction, genitourinary symptoms, and other disease processes that reduce the quality of life of affected women. The endocrine tumult of the menopause transition also exposes racial and socioeconomic disparities in the onset, severity, and frequency of symptoms. Hormone therapy (HT) treatment can be effective for perimenopausal symptoms but its use has been stymied by concerns about health risks observed in postmenopausal HT users who are older than 60 and/or women who have been postmenopausal for greater than 10 years.
Conclusions: The menopause transition is a disruptive process that can last for over a decade and causes symptoms in a majority of women. It is important for clinicians to recognize early signs and symptoms of the transition and be prepared to offer treatment to mitigate these symptoms. Many safe and effective options, including HT, are available.
The transition from reproductive to postreproductive life in women is called the menopausal transition and marks a significant milestone in the female life cycle. While the fundamental process of menopause is related directly to ovarian aging, all aspects of the hypothalamic-pituitary-ovarian-uterine axis are altered with time. Chronological and ovarian aging are 2 intertwined, concurrent processes that influence the pace of the process and its duration. Over recent decades, several worldwide studies of the menopausal transition have provided us with a chronology of reproductive and hormonal events that accompany the process. This chronology of ovarian aging has proven to be clinically useful in explaining the symptom experience of women undergoing the menopausal transition and has helped inform clinical practice.
The menopausal transition is roughly divided into 2 phases, which were initially based solely on menstrual patterns, but these patterns appears to have endocrine correlations. The early transition is characterized by a small increase in the prevalence of common menopausal symptoms, but perturbation of menstrual cycles is minimal, with women having at least 1 menstrual cycle within the past 3 months. During this time, a variety of compensatory endocrine mechanisms, such as elevated follicle-stimulating hormone (FSH), work to maintain cyclicity on a background of increasingly low numbers of remaining ovarian follicles. The analogy of subclinical hypothyroidism is apt, as it, too, is a situation in which trophic hormone secretion rises as the thyroid gland struggles to maintain adequate output of T3 and T4. By the time a woman attains the late transition, she has substantial evidence of estrogen deficiency, i.e., the ovarian failure can no longer be compensated for by changes in ovarian and pituitary hormone production. This phase is associated with an uptick in symptoms and reflects a time when bone mineral loss begins to be detectable. This mini-review provides an overview of the basic endocrine physiology of the transition, its common clinical manifestations, and an approach to clinical management.
J Clin Endocrinol Metab. 2021;106(1):1-15. © 2021 Endocrine Society